Research ExplorerPublicationsDesign of the Weight-loss Endoscopy Trial (WET): a multi-cen...

Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure

Standard

Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. / Hollenbach, Marcus; Prettin, Christiane; Gundling, Felix; Schepp, Wolfgang; Seufert, Jochen; Stein, Jürgen; Rösch, Thomas; Aberle, Jens; Feisthammel, Jürgen; Petroff, David; Hoffmeister, Albrecht.

In: BMC GASTROENTEROL, Vol. 18, No. 1, 18.07.2018, p. 118.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hollenbach, M, Prettin, C, Gundling, F, Schepp, W, Seufert, J, Stein, J, Rösch, T, Aberle, J, Feisthammel, J, Petroff, D & Hoffmeister, A 2018, 'Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure', BMC GASTROENTEROL, vol. 18, no. 1, pp. 118. https://doi.org/10.1186/s12876-018-0838-3

APA

Hollenbach, M., Prettin, C., Gundling, F., Schepp, W., Seufert, J., Stein, J., Rösch, T., Aberle, J., Feisthammel, J., Petroff, D., & Hoffmeister, A. (2018). Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC GASTROENTEROL, 18(1), 118. https://doi.org/10.1186/s12876-018-0838-3

Vancouver

Hollenbach M, Prettin C, Gundling F, Schepp W, Seufert J, Stein J et al. Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC GASTROENTEROL. 2018 Jul 18;18(1):118. https://doi.org/10.1186/s12876-018-0838-3

Bibtex

@article{c388262f5a8e4f1c99afaf13e1fabdff,
title = "Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure",
abstract = "BACKGROUND: Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these devices has not been undertaken or shown to be superior to a sham procedure.METHODS: We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated.DISCUSSION: This trial could help to identify the most effective and safest endoscopic device, thus determining the new standard procedure for endoscopic bariatric treatment.TRIAL REGISTRATION: 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).",
keywords = "Journal Article",
author = "Marcus Hollenbach and Christiane Prettin and Felix Gundling and Wolfgang Schepp and Jochen Seufert and J{\"u}rgen Stein and Thomas R{\"o}sch and Jens Aberle and J{\"u}rgen Feisthammel and David Petroff and Albrecht Hoffmeister",
year = "2018",
month = jul,
day = "18",
doi = "10.1186/s12876-018-0838-3",
language = "English",
volume = "18",
pages = "118",
journal = "BMC GASTROENTEROL",
issn = "1471-230X",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure

AU - Hollenbach, Marcus

AU - Prettin, Christiane

AU - Gundling, Felix

AU - Schepp, Wolfgang

AU - Seufert, Jochen

AU - Stein, Jürgen

AU - Rösch, Thomas

AU - Aberle, Jens

AU - Feisthammel, Jürgen

AU - Petroff, David

AU - Hoffmeister, Albrecht

PY - 2018/7/18

Y1 - 2018/7/18

N2 - BACKGROUND: Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these devices has not been undertaken or shown to be superior to a sham procedure.METHODS: We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated.DISCUSSION: This trial could help to identify the most effective and safest endoscopic device, thus determining the new standard procedure for endoscopic bariatric treatment.TRIAL REGISTRATION: 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).

AB - BACKGROUND: Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these devices has not been undertaken or shown to be superior to a sham procedure.METHODS: We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated.DISCUSSION: This trial could help to identify the most effective and safest endoscopic device, thus determining the new standard procedure for endoscopic bariatric treatment.TRIAL REGISTRATION: 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).

KW - Journal Article

U2 - 10.1186/s12876-018-0838-3

DO - 10.1186/s12876-018-0838-3

M3 - SCORING: Journal article

C2 - 30021518

VL - 18

SP - 118

JO - BMC GASTROENTEROL

JF - BMC GASTROENTEROL

SN - 1471-230X

IS - 1

ER -